New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 8, Pages 1689
Publisher
MDPI AG
Online
2017-08-03
DOI
10.3390/ijms18081689
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pdxdc1 modulates prepulse inhibition of acoustic startle in the mouse
- (2017) L A Feldcamp et al. Translational Psychiatry
- The Cholinergic System: An Emerging Drug Target for Schizophrenia
- (2016) Andrew Gibbons et al. CURRENT PHARMACEUTICAL DESIGN
- Schizophrenia risk from complex variation of complement component 4
- (2016) Aswin Sekar et al. NATURE
- The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression
- (2016) Yong-Ku Kim et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Anti-NMDA receptor encephalitis, autoimmunity, and psychosis
- (2016) Matthew S. Kayser et al. SCHIZOPHRENIA RESEARCH
- Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study
- (2016) Alexis C. Edwards et al. SCHIZOPHRENIA RESEARCH
- Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?
- (2016) P. Steullet et al. SCHIZOPHRENIA RESEARCH
- Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
- (2015) Bart A. Ellenbroek et al. BEHAVIOURAL PHARMACOLOGY
- Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity
- (2015) Jeremy Hall et al. BIOLOGICAL PSYCHIATRY
- Schizophrenia as a Disorder of Molecular Pathways
- (2015) Szatmár Horváth et al. BIOLOGICAL PSYCHIATRY
- Drug development in schizophrenia
- (2015) Donald C. Goff CURRENT OPINION IN PSYCHIATRY
- Potential serotonergic agents for the treatment of schizophrenia
- (2015) Ricardo P. Garay et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?
- (2015) John Dunlop et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Functional brain connectivity phenotypes for schizophrenia drug discovery
- (2015) Neil Dawson et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Schizophrenia biomarkers: Translating the descriptive into the diagnostic
- (2015) Benjamin S Pickard JOURNAL OF PSYCHOPHARMACOLOGY
- Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
- (2015) Arann R Rowe et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry
- (2015) Francine M. Benes SCHIZOPHRENIA RESEARCH
- Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy
- (2015) Hans-Gert Bernstein et al. SCHIZOPHRENIA RESEARCH
- Nicotinic ACh receptors as therapeutic targets in CNS disorders
- (2015) Kelly T. Dineley et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Brain-specific epigenetic markers of schizophrenia
- (2015) L F Wockner et al. Translational Psychiatry
- Cannabis and Schizophrenia
- (2015) J. A. Pushpa-Rajah et al. SCHIZOPHRENIA BULLETIN
- Developmental expression profiles of axon guidance signaling and the immune system in the marmoset cortex: Potential molecular mechanisms of pruning of dendritic spines during primate synapse formation in late infancy and prepuberty (I)
- (2014) Tetsuya Sasaki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
- (2014) Felice Iasevoli et al. Current Neuropharmacology
- The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
- (2014) Kathryn Gill et al. CURRENT PHARMACEUTICAL DESIGN
- A Dopamine D2 Receptor-DISC1 Protein Complex may Contribute to Antipsychotic-Like Effects
- (2014) Ping Su et al. NEURON
- Losing Control Under Ketamine: Suppressed Cortico-Hippocampal Drive Following Acute Ketamine in Rats
- (2014) Rosalyn J Moran et al. NEUROPSYCHOPHARMACOLOGY
- Correlations Between Brain Structure and Symptom Dimensions of Psychosis in Schizophrenia, Schizoaffective, and Psychotic Bipolar I Disorders
- (2014) J. L. Padmanabhan et al. SCHIZOPHRENIA BULLETIN
- Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA
- (2014) M. Kenk et al. SCHIZOPHRENIA BULLETIN
- Epigenetic mechanisms of importance for drug treatment
- (2014) Maxim Ivanov et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- α7-Nicotinic Acetylcholine Receptor Agonists for Cognitive Enhancement in Schizophrenia
- (2013) Robert Freedman Annual Review of Medicine
- Presynaptic Striatal Dopamine Dysfunction in People at Ultra-high Risk for Psychosis: Findings in a Second Cohort
- (2013) Alice Egerton et al. BIOLOGICAL PSYCHIATRY
- Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study
- (2013) Oliver D. Howes et al. BRAIN
- Psychopharmacology of the negative symptoms: Current status and prospects for progress
- (2013) Michael C. Davis et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
- (2013) E M P Poels et al. MOLECULAR PSYCHIATRY
- Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review
- (2013) Taro Kishi et al. NEUROMOLECULAR MEDICINE
- Inflammation and the two-hit hypothesis of schizophrenia
- (2013) Keith A. Feigenson et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Attenuated psychosis syndrome in DSM-5
- (2013) Ming T. Tsuang et al. SCHIZOPHRENIA RESEARCH
- Definition and description of schizophrenia in the DSM-5
- (2013) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- The Emerging Potential of Pharmacogenetics in Psychiatry
- (2012) Francis E. Lotrich AMERICAN JOURNAL OF PSYCHIATRY
- The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease
- (2012) Alexander H. Stephan et al. Annual Review of Neuroscience
- The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment
- (2012) Oliver D. Howes et al. ARCHIVES OF GENERAL PSYCHIATRY
- Treating Schizophrenia: Novel Targets for the Cholinergic System
- (2012) T.T. Money et al. CNS & Neurological Disorders-Drug Targets
- Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia
- (2012) Amirhossein Modabbernia et al. CNS DRUGS
- Treating Impaired Cognition in Schizophrenia
- (2012) H. M. Ibrahim et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
- (2012) Antonio Waldo Zuardi et al. CURRENT PHARMACEUTICAL DESIGN
- From prediction error to incentive salience: mesolimbic computation of reward motivation
- (2012) Kent C. Berridge EUROPEAN JOURNAL OF NEUROSCIENCE
- Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
- (2012) Imran B Chaudhry et al. JOURNAL OF PSYCHOPHARMACOLOGY
- An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
- (2012) Mark J. Millan NEUROPHARMACOLOGY
- Putative neuroprotective agents in neuropsychiatric disorders
- (2012) Seetal Dodd et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
- (2012) Kyoung-Sae Na et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins
- (2012) A. de Bartolomeis et al. PSYCHOPHARMACOLOGY
- A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies
- (2012) Jessica Jackson et al. SCHIZOPHRENIA RESEARCH
- Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse, and Parkinson’s Disease
- (2011) Ditte Dencker et al. ACS Chemical Neuroscience
- Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
- (2011) Shigeyuki Chaki et al. CURRENT PHARMACEUTICAL DESIGN
- Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia
- (2011) Judith Usall et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Pharmacogenetics in psychiatry: translating research into clinical practice
- (2011) A K Malhotra et al. MOLECULAR PSYCHIATRY
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- (2011) Carrie K Jones et al. NEUROPSYCHOPHARMACOLOGY
- Alpha7 Nicotinic Acetylcholine Receptors Modulate Motivation to Self-Administer Nicotine: Implications for Smoking and Schizophrenia
- (2011) Darlene H Brunzell et al. NEUROPSYCHOPHARMACOLOGY
- From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
- (2011) Bita Moghaddam et al. NEUROPSYCHOPHARMACOLOGY
- Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence
- (2011) C.E. Marx et al. NEUROSCIENCE
- Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
- (2010) G. Paul Amminger et al. ARCHIVES OF GENERAL PSYCHIATRY
- The neurobiology of schizophrenia: new leads and avenues for treatment
- (2010) Nicholas J Bray et al. CURRENT OPINION IN NEUROBIOLOGY
- Abnormal neural oscillations and synchrony in schizophrenia
- (2010) Peter J. Uhlhaas et al. NATURE REVIEWS NEUROSCIENCE
- Epigenetic GABAergic targets in schizophrenia and bipolar disorder
- (2010) A. Guidotti et al. NEUROPHARMACOLOGY
- Schizophrenia and the Motivation for Smoking
- (2010) Cheryl Forchuk et al. PERSPECTIVES IN PSYCHIATRIC CARE
- Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia
- (2010) W Liu et al. PHARMACOGENOMICS JOURNAL
- Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
- (2010) Norbert Müller et al. SCHIZOPHRENIA RESEARCH
- Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
- (2010) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- The complement system in schizophrenia
- (2009) K.R. Mayilyan et al. DRUG NEWS & PERSPECTIVES
- Cannabis and psychosis/schizophrenia: human studies
- (2009) Deepak Cyril D’Souza et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Driving fast-spiking cells induces gamma rhythm and controls sensory responses
- (2009) Jessica A. Cardin et al. NATURE
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- Role of the cholinergic system in the pathology and treatment of schizophrenia
- (2008) Elizabeth Scarr et al. Expert Review of Neurotherapeutics
- Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]
- (2008) A. Satow et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
- (2008) Josep Dalmau et al. LANCET NEUROLOGY
- Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia
- (2008) Paul C. Fletcher et al. NATURE REVIEWS NEUROSCIENCE
- Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
- (2008) M. J. Arranz et al. SCHIZOPHRENIA BULLETIN
- Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
- (2008) M KESHAVAN et al. SCHIZOPHRENIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started